These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19188164)

  • 41. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
    Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
    Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
    Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
    Li R; Zatloukalova P; Muller P; Gil-Mir M; Kote S; Wilkinson S; Kemp AJ; Hernychova L; Wang Y; Ball KL; Tao K; Hupp T; Vojtesek B
    Cell Mol Biol Lett; 2020; 25():41. PubMed ID: 32874188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
    Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
    Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
    Shen H; Maki CG
    J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
    Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
    J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.
    Logan IR; McNeill HV; Cook S; Lu X; Lunec J; Robson CN
    Prostate; 2007 Jun; 67(8):900-6. PubMed ID: 17440969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
    Jones RJ; Chen Q; Voorhees PM; Young KH; Bruey-Sedano N; Yang D; Orlowski RZ
    Clin Cancer Res; 2008 Sep; 14(17):5416-25. PubMed ID: 18765533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
    Park EJ; Choi KS; Yoo YH; Kwon TK
    Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
    Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
    Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.
    Hashimoto T; Ichiki T; Ikeda J; Narabayashi E; Matsuura H; Miyazaki R; Inanaga K; Takeda K; Sunagawa K
    Cardiovasc Res; 2011 Sep; 91(4):711-9. PubMed ID: 21498419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
    Aziz MH; Shen H; Maki CG
    Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
    Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
    Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.